Ipilimumab
Cetuximab
Tianjin Medical University Cancer Institute and Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Cetuximab cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Meng Qiu | Phase 3 | BB |
FLUOROURACILUM Meng Qiu | Phase 3 | BB |
Calcium folinate pentahydrate Meng Qiu | Phase 3 | BB |
Eloxatin Meng Qiu | Phase 3 | BB |
Cetuximab Tianjin Medical University Cancer Institute and Hospital | Phase 3 | B |
Dabrafenib Tianjin Medical University Cancer Institute and Hospital | Phase 2 | CCC |
Crisaborole Sun Yat-sen University | Phase 2 | CCC |
5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE Shanghai Minimally Invasive Surgery Center | D |
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →